1. Generics Bulletin

Celltrion Healthcare Gears Up For Infliximab SC Launch

UK Commercial Head Reveals Strategy For Innovative Biosimilar Infliximab

 
• By Dave Wallace

As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.

Innovation_Button
Highlighting Remsima (infliximab) SC’s innovative aspects will be at the heart of Celltrion Healthcare’s strategy • Source: Shutterstock

Having late last year received a pan-European marketing authorization for the world’s first subcutaneous formulation of infliximab, Celltrion Healthcare is preparing to launch the Remsima SC product imminently in its first European markets, the UK and Germany. (Also see "Celltrion’s Remsima SC Ready For Early 2020 Launch" - Generics Bulletin, 26 November, 2019.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products